Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark

INTRODUCTION: With longer life expectancy in people living with HIV (PLWH) on antiretroviral therapy, cardiovascular disease (CVD) has become a common cause of mortality among them. Abacavir has been associated with an increased risk of myocardial infarction, but the mechanism is unknown. Additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Karen Brorup Heje, Knudsen, Andreas, Møller, Søren, Siebner, Hartwig Roman, Hove, Jens Dahlgaard, Gerstoft, Jan, Benfield, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445393/
https://www.ncbi.nlm.nih.gov/pubmed/37604629
http://dx.doi.org/10.1136/bmjopen-2023-075673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445393/
https://www.ncbi.nlm.nih.gov/pubmed/37604629
http://dx.doi.org/10.1136/bmjopen-2023-075673

Ejemplares similares